80 infected patients will receive tamoxifen 20 mg orally twice daily with a glass of water and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days

80 infected patients will receive tamoxifen 20 mg orally twice daily with a glass of water and after three days of tamoxifen therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days

No study treatment Arm No Isotretinoin or Tamoxofien treatment

COVID-19

20 mg PO (by mouth) twice daily for 14 days
13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days starting after three days of taking tamoxifen

Drug: Isotretinoin plus Tamoxifen

20 mg PO (by mouth) twice daily for 14 days
Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days starting after three days of taking tamoxifen

Aerosolized Isotretinoin plus Tamoxifen

Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus

Proportion of lung injury score decreased or increased after treatment

Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon

less than 250 ng/mL, or less than 0.4 mcg/mL of blood sample

Mahmoud Ramadan mohamed Elkazzaz

Principal Investigator

Kafrelsheikh University

Arm 1: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days combined with the standard therapy . All subjects were encouraged to complete the full course of treatment and common side effects were explained. Side effects and compliance will be documented.

Arm 2: infected patients will receive the standard therapy for COVID-19 (Paracetamol 500 mg /6h, Hydroxychloroquine 500 mg/ 12h, Oseltamivir 150 mg /12 h for 5 days, Azithromycin 1 gm first day then 500 mg/day for 1st line or Clarithromycin 500 mg/12 h for 7-14 days, Ascorbic acid 500 mg/12 h and Cyanocobalamin IV once daily plus Lopinavir 400mg/Ritonavir 100 mg caps 2 capsules twice daily in severe cases) and after three days of the standard therapy the infected patients will receive Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days

Arm 3:infected patients will receive the standard therapy for COVID-19 for 14 days

COVID19

After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment
Standard treatment is according to the protocol of treatment of 2019-nCoV infection

Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment

Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment
Standard treatment is according to the protocol of treatment of 2019-nCoV infection

Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment

Standard treatment is according to the protocol of treatment of 2019-nCoV infection

Standard treatment

Faculty of Medicine, Kafr El-sheikh University

Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 (Randomized)

Isotretinoin in Treatment of COVID-19 (Randomized)

Sponser Investigator

Patients and method :
This study will performed on 1000 patients tested positive for the presence of COVID-19 RNA by RT-PCR kit for RNA detection will randomly divided into 3 equal groups

Patients
This study will performed on 1000 patients tested positive for the presence of COVID-19 RNA by RT-PCR kit for RNA detection will randomly divided into 3 equal groups

Patients will be randomized in a 1:1 ratio to receive Prosta-Q, one capsule, twice daily for 4-6 weeks after brachytherapy placement.
Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared.

Patients will be randomized in a 1:1 ratio to receive Placebo, one capsule, twice daily for 4-6 weeks after brachytherapy placement.
Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared.

Prostate Adenocarcinoma

Prosta-Q is an over-the-counter herbal supplement manufactured by Farr Laboratories. It is a combination product composed of quercetin, cranberry, saw palmetto, bromelain, and papain.

Prosta-Q

Placebo

Trial of Supplement of Quercetin, Bromelain & Papain on Reducing Severity of Radiation-Induced Prostatitis

A Phase II Randomized Controlled Trial of a Supplement Containing Quercetin, Bromelain and Papain on Reducing the Severity of Radiation-Induced Prostatitis

difference in prostatitis symptoms between treatment and placebo group.

Health Related Quality of Life (HRQOL) will be assessed with pre- and post- treatment SHIM questionnaires
SHIM Scores 1-7 Severe Erectile Dysfunction (ED) 8-11 Moderate ED 12-16 Mild to Moderate ED 17-21 Mild ED 22-25 No signs of ED

inflammation markers will be collected pre- and post-brachytherapy for comparison between treatment and placebo groups.

To assess safety of Prosta-Q compared to placebo.

Health Related Quality of Life (HRQOL) will be assessed with pre- and post- treatment EPIC questionnaires. Items are standardized to a 0-100 scale and are averaged to calculate a summary score or subscale score.

Health Related Quality of Life (HRQOL) will be assessed with pre- and post- treatment I-PSS questionnaires.
American Urological Association Symptom (AUA) Score Mild = 0-7 Moderate = 8-19 Severe = 20-35

Health Related Quality of Life (HRQOL) will be assessed with pre- and post- treatment questionnaires. Responses to the questions are added up for a total between 0-27. Question 10 does not count toward the total score.

University of Utah

An asymmetric two-sided group sequential design will be used with an interim analysis for efficacy and futility.

papain/neoplasms

Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus

Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 (Randomized)

Trial of Supplement of Quercetin, Bromelain & Papain on Reducing Severity of Radiation-Induced Prostatitis

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen